131885-79-5

Basic information

• Product Name: 1-(3,4-DIAMINOPHENYL)-1H-IMIDAZOLE
• Synonyms: 1-(3,4-DIAMINOPHENYL)-1H-IMIDAZOLE
• CAS NO: 131885-79-5
• Molecular Formula: C₉H₁₀N₄
• Molecular Weight: 174.206
• Mol File: 131885-79-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3,4-DIAMINOPHENYL)-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-DIAMINOPHENYL)-1H-IMIDAZOLE(131885-79-5)
• EPA Substance Registry System: 1-(3,4-DIAMINOPHENYL)-1H-IMIDAZOLE(131885-79-5)

Safety Data

• Hazardous Substances Data: 131885-79-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3,4-DIAMINOPHENYL)-1H-IMIDAZOLE is used as a chemical compound for the development of drugs targeting various medical conditions. Its unique structure and potential biological activity make it a promising candidate for pharmaceutical research and drug design.
Used as a Chemical Intermediate:
In the field of organic chemistry, 1-(3,4-DIAMINOPHENYL)-1H-IMIDAZOLE serves as a chemical intermediate for the synthesis of other organic compounds. Its aromatic nature and reactivity with other molecules facilitate the creation of new chemical entities with specific properties and applications.
Used in Research and Development:
Due to its potential biological activity and interesting chemical properties, 1-(3,4-DIAMINOPHENYL)-1H-IMIDAZOLE is used as a subject of study for researchers and scientists. This helps in understanding its properties, exploring its potential uses, and developing new applications in various industries, including pharmaceuticals, materials science, and chemical engineering.

Upstream product

• 1635-61-6 5-chloro-2-nitroaniline 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 611-06-3 2,4-dichloronitrobenzene 
• 131885-65-9 5-(1H-imidazol-1-yl)-2-nitroaniline 

Downstream Products

• 872870-31-0 N-[4-(imidazol-1-yl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide 

Relevant articles and documents

BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING SAME

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1 ), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

Synthesis and Catalytic Applications of Heterobimetallic Carbene Complexes Obtained via Sequential Metalation of Two Bisazolium Salts

A simple sequential metalation approach starting from the imidazolium/benzimidazolium salt 4(I)2 yielded the heterobimetallic RhIII/M (M = PdII, IrI, AuI, RuII) complexes [6]-[9]. Alternatively, a symmetrical 1,3-imidazolium substituted benzene was used for the preparation of the heterobimetallic M′/PdII (M′ = RhIII, IrIII) complexes [12] and [13]. The versatile stepwise approach used for the preparation of complexes [6]-[9] involved the deprotonation reaction of the bisazolium salt 4(I)2 in the presence of [RhCp?(Cl)2]2 to afford the monometallic complex [5]I featuring a chelating coordinated bidentate CNHC^Cphenyl ligand. Complex [5]I was reacted with Ag2O to give a nonisolated RhIII/AgI complex which in a subsequent transmetalation reaction yielded the heterobimetallic RhIII/M bis-NHC complexes (M = PdII [6], IrI [7], AuI [8], RuII [9]). Similarly, heterobimetallic M′/PdII bis-NHC complexes [12] (M′ = RhIII) and [13] (M′ = IrIII) have been prepared from a symmetrical bisazolium salt by generating first the monometallic M′ complexes followed by a transmetalation reaction of the in situ generated M′/AgI complexes with [Pd(dmba)(μ-Cl)]2. The RhIII/PdII complexes [6] and [12] and the IrIII/PdII complex [13] were used as catalysts for two orthogonal tandem reactions, namely, the Suzuki-Miyaura coupling/transfer hydrogenation and the Suzuki-Miyaura-coupling/α-alkylation of ketones. The catalytic activity of the heterobimetallic complexes was compared to mixtures of the related monometallic analogues [14]-[17], with the heterobimetallic complexes generally showing a higher catalytic activity. In addition, nBuOH was found to play a dual role as an alkylating and reducing agent in the Suzuki-Miyaura coupling/α-alkylation of ketones.

SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY

The invention provides PKA and PKB kinase-inhibiting compounds of the formula (I); or salts, solvates, tautomers or N-oxides thereof, wherein E is a five membered heteroaryl ring containing 1, 2, 3 or 4 heteroatoms selected from O, N and S provided that no more than 1 heteroatom may be other than N; q and r are each is 0 or 1; provided that q+r is 1 or 2; T is N or a group CR5; J1-J2 is N=C(R6), (R7)C=N, (R8)N- C(O), (R8)2C-C(O), N=N or (R7)C=C(R6); Q3 is a bond or a saturated C1-3 hydrocarbon linker group optionally substituted by fluorine and hydroxy; G is NR2R3, CN or OH; m and n are each 0 or 1, provided that m+n is 1 or 2, and provided also that m or n are each 0 when the adjacent ring member of ring E is S or O; R1a and R1b are the same or different and each is hydrogen or a substituent R10; or R1a and R1b together with the carbon atoms or heteroatoms to which they are attached form a 5 or 6-membered aryl or heteroaryl ring, wherein the aryl or heteroaryl rings are optionally substituted by one or more substituents R10; and R2, R3, R4, R5, R7, R6, R8, and R10 are as defined in the claims.

OLIGOHETEROAROMATIC LUMINISCENT ASSEMBLIES AS HIGH-AFFINITY DNA SEQUENCE-DIRECTED LIGANDS

The present invention provides a novel class of oligoheteroaromatic assemblies with luminescence characteristics and composition based on integrated polyheterocyclic polyamide oligomers of multiple nitrogen-containing heteroaromatic of the general formula (I) This novel class of compounds of the present invention is capable of binding to targeted DNA sequence in the minor groove, and thus is useful for genomics applications. In particular, the compounds of the invention binds to the DNA at a binding stoichiometry of 2: 1 ternary complexation with very high affinity and sequence selectivity.

Sulfonamide-based compounds as protein tyrosine kinase inhibitors

Various sulfonamide-based compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.

Benzimidazole, benzoxazole and benzothiazole compounds

A compound of formula (I): wherein: R1 represents halogen or a different group as defined in the description, Ra and Rb, which mnay be identical or different, represent hydrogen, alkyl, or hydroxy, X represents oxygen or sulphur or NR, R being H or alkyl,

6-(1H-imidazol-1-yl)-7-nitro-2,3 (1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: Structure-activity relationships for the AMPA- type non-NMDA receptor

A novel series of quinoxalinediones possessing imidazolyl and related heteroaromatic substituents was synthesized and evaluated for their activity to inhibit [3H]AMPA binding from rat whole brain. From the structure- activity relationships, it was found that the 1H-imidazol-1-yl moiety could function as a bioisostere for the cyano and nitro groups, and that 6-(1H- imidazol-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione (11) showed the most potent activity for the AMPA receptor. Compound 11 was evaluated for selectivity versus other excitatory amino acid receptors, and its action against AMPA at its receptor in the rat striatum was characterized. These data showed that compound 11 was a selective antagonist for the AMPA receptor with a K(i) value of 0.084 μM, being approximately equipotent with 2,3-dihydro-6-nitro- 7-sulfamoylbenzo(f)quinoxaline (3) (NBQX; K(i) = 0.060 μM). Compound 11 was also found to give protection against sound-induced seizure on DBA/2 mice at the minimum effective dose of 3 mg/kg ip (3; 10 mg/kg ip).

Cardiotonic Agents. Synthesis and Cardiovascular Properties of Novel 2-Arylbenzimidazoles and Azabenzimidazoles

Novel 2-arylbenzimidazoles and azabenzimidazoles were synthesized, and their inotropic action was evaluated.Changes in left ventricular pressure, dP/dt max, were measured as an index of cardiac contractility.The structural features that impart optimal inotropic activity are presented.The most potent compounds were evaluated orally in conscious dogs with implanted Konigsberg pressure transducers.To investigate the mechanism of action, the most potent compounds were tested for their calcium-sensitizing properties and their potential for the inhibition of phosphodiesterase.Two compounds, 1 and 41, showed interesting in vitro and oral activity without side effects.They have a more potent calcium-sensitizing effect than MCI-154 and are under further investigation.